Targeting non-canonical NF-κB signalling in CYLD cutaneous syndrome by selective inhibition of IκB kinase alpha.
Kirsty Hodgson, Joseph Inns, Gary Reynolds, Emily Stephenson, Andrew Paul, Naomi Sinclair, Giacomo Berretta, Christopher P. A. T. Lawson, Andrew Michael Frey, Iglika G. Ivanova, Éva Ádám, Christopher J. Lord, Simon Cockell, Jonathan M Coxhead, Nikoletta Nagy, , Neil Rajan
This study identifies non-canonical NF-κB signalling as a therapeutic target in CYLD cutaneous syndrome and shows that IKK inhibition reduces tumor viability in patient-derived models.
bioRxiv · Jan 31, 2025 · PreprintCancer Biology